Clinical trials: Hematological Disease
Chronic Kidney Diseases, Hypertension
Integrated Diagnosis and Treatment of CKD on Outcomes
Objective: To establish a study cohort and follow up of patients with CKD in our hospital, and evaluate the status of integrated CKD diagnosis and treatment according to guidelines in the real world, as well as the clinical…
- Conditions
- Chronic Kidney Diseases, Hypertension, Hyperglycemia, Hyperlipidemias
- Trial name
- NCT05242055
- Testing
- Integrated diagnosis and treatment for CKD
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Capital Medical University
Anemia
Periconceptional Iron Supplementation in Rural Bangladesh
The investigators hypothesize that periconceptional iron supplementation to married, nulliparous women in rural Bangladesh will significantly reduce anemia and improve hemoglobin concentrations before and during pregnancy.
- Trial name
- NCT00953134
- Testing
- Ferrous fumarate (iron), folic acid
- Where
- Bangladesh
- Volunteers
- 273 people, healthy volunteers welcome
- Sponsor
- The Hospital for Sick Children
Childhood Cancer, Acute Lymphoblastic Leukemia
Quality of Life in Children With Cancer
Childhood cancers cover a wide range of diseases; leukemia, central nervous system cancers and lymphomas are the most common ones among them.
- Conditions
- Childhood Cancer, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- sıcc (NCT03190499)
- Testing
- Family based assessment
- Where
- Turkey (Türkiye)
- Volunteers
- 74 people
- Sponsor
- Cumhuriyet University
Multiple Myeloma
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
This study is designed to evaluate if treatment with adjuvant nivolumab improves depth of response in patients with relapsed refractory multiple myeloma (RRMM) who achieve a less-than-ideal response to idecaptagene vicleucel.
- Trial name
- NCT06523621
- Testing
- Nivolumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Wake Forest University Health Sciences
Acute Myelogenous Leukemia, Ovarian Cancer
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
- Conditions
- Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer
- Trial name
- NCT03761914
- Testing
- galinpepimut-S, pembrolizumab, Montanide
- Where
- 12 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sellas Life Sciences Group
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Role of Gut Microbiome in Cancer Therapy
This study examines how gut microbiome can affect cancer therapy in cancer patients undergoing cancer therapy or stem cell transplant. The human microbiome affects the way some cancer drugs are metabolized in the human body.
- Trial name
- NCT05112614
- Testing
- Biospecimen Collection, Electronic Health Record Review
- Where
- 3 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- Mayo Clinic
Acute Myeloid Leukemia, Myelodysplastic Syndrome
A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Phase 1a is an open-label, multi-dose, single-arm, dose-escalation study to define the toxicity profile, pharmacokinetics, and antitumor activity of SGN-33 in patients with myelodysplastic syndrome (MDS), acute myelogenous…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia
- Trial name
- NCT00283114
- Testing
- lintuzumab
- Where
- 9 sites in United States
- Volunteers
- 82 people
- Sponsor
- Seagen Inc.
Myelodysplastic Syndromes
Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes
Phase I: To investigate maximum tolerated dose (MTD), safety and tolerability, pharmacokinetics, exploratory biomarker and efficacy of BI 836858 monotherapy in patients with low or intermediate-1 risk myelodysplastic syndromes…
- Trial name
- NCT02240706
- Testing
- Best Supportive Care, BI 836858
- Where
- 5 sites in United States, Germany
- Volunteers
- 27 people
- Sponsor
- Boehringer Ingelheim
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)
This phase II MATCH treatment trial tests how well larotrectinib (LOXO-101) works in treating patients with cancer that has certain genetic changes.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06390852
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
Treatment With Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) With Acute Myeloid Leukemia: A Single Institution Experience.
The treatment of very elderly patients (≥70 years) with acute myeloid leukemia remains controversial. Although the outcome in younger adults has improved because of cytarabine- and anthracycline-based chemotherapy with advanced…
- Trial name
- NCT03350152
- Where
- France
- Volunteers
- 302 people
- Sponsor
- Hospices Civils de Lyon
Multiple Myeloma
A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma
The purpose of this post marketing study is to determine the plasma concentration of bortezomib (unchanged drug) to assess the pharmacokinetic (PK - the study of the way a drug enters and leaves the blood and tissues over time)…
- Trial name
- NCT01801436
- Testing
- Bortezomib
- Volunteers
- 14 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)
This phase II MATCH treatment trial identifies the effects of copanlisib hydrochloride (copanlisib) in patients whose cancer has a genetic change called PIK3CA mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Refractory Lymphoma
- Trial name
- NCT05490771
- Testing
- Biopsy Procedure, Computed Tomography, Copanlisib Hydrochloride
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Leukaemia
PUMA (Paediatric Osseous Marrow Assessment)
This is a pilot cancer imaging study investigating change in the apparent diffusion coefficient (ADC) at a single time point post-transplantation in patients.
- Trial name
- PUMA (NCT03466944)
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Myelodysplastic Syndrome
Three Dosing Schedules of Oral Rigosertib in MDS Patients
This study will compare the dosing regimen of oral rigosertib, which has been used in other studies of lower risk Myelodysplastic Syndrome (MDS), with 2 new dosing regimens to determine if one of the new regimens gives improved…
- Trial name
- NCT02075034
- Testing
- rigosertib
- Where
- United States
- Sponsor
- Traws Pharma, Inc.
Lymphoma, Multiple Myeloma
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
The goal of this study is to evaluate the feasibility and preliminary efficacy of an artificial intelligence (AI)-generated personalized question prompt list (a list of suggested questions to ask during outpatient appointments)…
- Trial name
- NCT07226934
- Testing
- GPT-QPL
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Multiple Myeloma
Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients
The purpose of this study is to determine whether the association of Thalidomide to Melphalan and Prednisone is effective in the treatment of newly diagnosed elderly multiple myeloma.
- Trial name
- NCT00232934
- Testing
- Thalidomide
- Where
- 13 sites in Italy
- Volunteers
- 400 people
- Sponsor
- Gruppo Italiano per lo Studio del Mieloma Multiplo
Stunting, Anemia
Effectiveness Study During the First 1,000 Days in Kenya
Malnutrition is a public health problem in Kenya, with 26% of children underfive years of age stunted, and 26% of pre-school children, 26% of women of reproductive age and 42% of pregnant women being anaemic, respectively.
- Conditions
- Stunting, Anemia, Micronutrient Deficiency
- Trial name
- NCT03558464
- Testing
- Intervention (integrated package), Control
- Where
- Kenya
- Volunteers
- 1,199 people, healthy volunteers welcome
- Sponsor
- Fabian Rohner
Leukemia
Resistance to Methotrexate in Patients With Acute Lymphoblastic Leukemia in Relapse or Remission
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about cancer and the development of drug resistance in patients.
- Trial name
- NCT00899899
- Testing
- microarray analysis, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis
- Volunteers
- 135 people
- Sponsor
- Children's Oncology Group
Hematologic Malignancies
A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders
To investigate the safety of partially matched related human placental-derived stem cells (HPDSC) administered in conjunction with umbilical cord blood (UCB) stem cells from the same donor in subjects with various malignant or…
- Trial name
- HPDSC (NCT00596999)
- Testing
- UCB and HPDSC
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Celgene Corporation
Acute Myeloid Leukemia
MRD-guided Treatment in NPM1mut AML Patients
Evaluation the safety and efficacy of Pembrolizumab (PEM) when administered in combination with standard Azacitidine (AZA) in nucleophosmin (NPM1) mutated AML patients with molecular relapse defined by the presence of measurable…
- Trial name
- PEMAZA (NCT03769532)
- Testing
- Pembrolizumab, Azacitidine
- Where
- 10 sites in Germany
- Volunteers
- 26 people
- Sponsor
- Technische Universität Dresden
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.